UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM N-Q
CERTIFIED SHAREHOLDER REPORT OF REGISTERED
MANAGEMENT INVESTMENT COMPANIES
Investment Company Act file number 811-23108
Amplify ETF Trust
(Exact name of registrant as specified in charter)
310 South Hale Street, Wheaton, IL 60187
(Address of principal executive offices) (Zip code)
National Corporate Research, Ltd., 10 Milk Street, Suite 1055, Boston, MA 02108
(Name and address of agent for service)
855-267-3837
Registrant's telephone number, including area code
Date of fiscal year end: October 31
Date of reporting period: January 31, 2020
ITEM 1. SCHEDULE OF INVESTMENTS
|
Amplify Seymour Cannabis ETF
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Schedule of Investments
|
|
|
|
|
|
|
|
|
|
(Unaudited)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
As of January 31, 2020
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Shares
|
|
Value (Note 1)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
COMMON STOCKS - 94.08%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Consumer Discretionary - 2.14%
|
|
|
|
|
|
|
|
|
|
*
|
GrowGeneration Corp.
|
|
|
|
|
|
22,656
|
$
|
107,843
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Consumer Staples - 5.93%
|
|
|
|
|
|
|
|
|
|
|
*
|
Neptune Wellness Solutions, Inc.
|
|
|
|
|
67,472
|
|
159,909
|
|
|
*
|
Village Farms International, Inc.
|
|
|
|
|
25,440
|
|
138,902
|
|
|
|
|
|
|
|
|
|
|
|
|
298,811
|
|
|
Financials - 11.88%
|
|
|
|
|
|
|
|
|
|
|
|
Canaccord Genuity Group, Inc.
|
|
|
|
|
27,368
|
|
101,715
|
|
|
*
|
Canopy Rivers, Inc.
|
|
|
|
|
|
169,344
|
|
163,741
|
|
|
*
|
Charlottes Web Holdings, Inc.
|
|
|
|
|
24,472
|
|
177,282
|
|
|
*
|
Silver Spike Acquisition Corp.
|
|
|
|
|
15,248
|
|
155,530
|
|
|
|
|
|
|
|
|
|
|
|
|
598,268
|
|
|
Health Care - 69.82%
|
|
|
|
|
|
|
|
|
|
|
*
|
Aleafia Health, Inc
|
|
|
|
|
|
122,248
|
|
58,178
|
|
|
*
|
Aphria, Inc.
|
|
|
|
|
|
67,424
|
|
315,270
|
|
|
*
|
Arena Pharmaceuticals, Inc.
|
|
|
|
|
3,480
|
|
159,001
|
|
|
*
|
Aurora Cannabis, Inc.
|
|
|
|
|
|
61,904
|
|
116,999
|
|
|
*
|
Canopy Growth Corp.
|
|
|
|
|
|
23,632
|
|
532,902
|
|
|
*
|
Cara Therapeutics, Inc.
|
|
|
|
|
|
9,360
|
|
150,696
|
|
|
*
|
cbdMD, Inc.
|
|
|
|
|
|
30,760
|
|
31,990
|
|
|
*
|
Cronos Group, Inc.
|
|
|
|
|
|
52,776
|
|
378,932
|
|
|
*
|
GW Pharmaceuticals PLC
|
|
|
|
|
|
4,272
|
|
493,544
|
|
|
*
|
HEXO Corp.
|
|
|
|
|
|
37,192
|
|
46,490
|
|
|
*
|
MediPharm Labs Corp.
|
|
|
|
|
|
79,384
|
|
168,507
|
|
|
*
|
Organigram Holdings, Inc.
|
|
|
|
|
|
81,040
|
|
209,894
|
|
|
|
PerkinElmer, Inc.
|
|
|
|
|
|
2,776
|
|
256,724
|
|
|
*
|
PharmaCielo Ltd.
|
|
|
|
|
|
54,176
|
|
118,272
|
|
|
*
|
Sundial Growers, Inc.
|
|
|
|
|
|
45,896
|
|
55,075
|
|
|
*
|
Supreme Cannabis Co.
|
|
|
|
|
|
228,600
|
|
83,752
|
|
|
*
|
Tilray, Inc.
|
|
|
|
|
|
6,600
|
|
115,764
|
|
|
*
|
Weedmd, Inc.
|
|
|
|
|
|
170,000
|
|
97,598
|
|
|
*
|
Zynerba Pharmaceuticals, Inc.
|
|
|
|
|
25,128
|
|
126,645
|
|
|
|
|
|
|
|
|
|
|
|
|
3,516,233
|
|
|
Industrials - 4.31%
|
|
|
|
|
|
|
|
|
|
|
*
|
Akerna Corp.
|
|
|
|
|
|
4,096
|
|
33,260
|
|
|
*
|
Auxly Cannabis Group, Inc.
|
|
|
|
|
|
205,032
|
|
96,026
|
|
|
*
|
The Flowr Corp.
|
|
|
|
|
|
67,936
|
|
87,755
|
|
|
|
|
|
|
|
|
|
|
|
|
217,041
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total Common Stocks (Cost $7,213,528)
|
|
|
|
|
|
|
4,738,196
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(Continued)
|
|
Amplify Seymour Cannabis ETF
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Schedule of Investments
|
|
|
|
|
|
|
|
|
|
(Unaudited)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
As of January 31, 2020
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Shares
|
|
Value (Note 1)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
REAL ESTATE INVESTMENT TRUST - 5.45%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Innovative Industrial Properties, Inc.
|
|
|
|
|
3,064
|
$
|
274,228
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total Real Estate Investment Trust (Cost $292,509)
|
|
|
|
|
|
274,228
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total Value of Investments (Cost $7,506,037) - 99.53%
|
|
|
|
|
$
|
5,012,424
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other Assets Less Liabilities - 0.47%
|
|
|
|
|
|
|
23,603
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net Assets - 100.00%
|
|
|
|
|
|
|
$
|
5,036,027
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(a)
|
Aggregate cost for financial reporting and federal income tax purposes is the same. Unrealized appreciation (depreciation) of investments for financial reporting
and federal income tax purposes is as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Aggregate gross unrealized appreciation
|
|
|
|
|
|
$
|
19,006
|
|
|
Aggregate gross unrealized depreciation
|
|
|
|
|
|
|
(2,512,619)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net unrealized depreciation
|
|
|
|
|
|
|
$
|
(2,493,613)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Summary of Investments
|
% of Net
|
|
|
|
|
|
|
|
|
|
|
by Sector
|
|
Assets
|
|
Value
|
|
|
|
|
|
|
|
|
Common Stocks:
|
|
|
|
|
|
|
|
|
|
|
|
|
Communication Services
|
2.14%
|
|
$
|
107,843
|
|
|
|
|
|
|
|
|
Consumer Staples
|
|
5.93%
|
|
298,811
|
|
|
|
|
|
|
|
|
Financials
|
|
11.88%
|
|
598,268
|
|
|
|
|
|
|
|
|
Health Care
|
|
69.82%
|
|
3,516,233
|
|
|
|
|
|
|
|
|
Industrials
|
|
4.31%
|
|
217,041
|
|
|
|
|
|
|
|
|
Real Estate Investment Trust
|
5.45%
|
|
274,228
|
|
|
|
|
|
|
|
|
Other Assets Less Liabilities
|
0.47%
|
|
23,603
|
|
|
|
|
|
|
|
|
Total Net Assets
|
|
100.00%
|
|
$
|
5,036,027
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(Continued)
|
|
Amplify Seymour Cannabis ETF
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Schedule of Investments - Continued
|
|
|
|
|
|
|
|
|
(Unaudited)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
As of January 31, 2020
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Note 1 - Investment Valuation
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Investments are stated at value as of the close of regular trading on the New York Stock Exchange (NYSE), normally at 4:00 P.M., Eastern Time. In order to value the
securities, the Fund uses the following valuation techniques: Equity securities held by the Fund are valued at the last sale price or official closing price on the exchange or principal where the security was acquired or most likely will be
sold. In the event there were no sales during the day or closing prices are not available, the securities are valued using the last available bid price. Investments by the fund in open-end mutual funds are valued at their respective net
asset values each business day. Other portfolio securities and assets, for which reliable market quotations are not readily available, are valued at fair value as determined in good faith by the Fund’s Pricing Committee following procedures
established by the Board of Trustees.
|
|
|
The frequency with which these fair valuation procedures are used cannot be predicted and fair value of securities may differ significantly from the value that
would have been used had a ready market for such securities existed. A three-tier hierarchy to prioritize the pricing assumptions, referred to as inputs, used in valuation techniques to measure fair value.
|
|
Level 1 securities valued using quoted prices in active markets for identical securities. Level 2 includes securities valued using other significant observable
inputs.Observable inputs may include quoted prices for similar securities, interest rates, prepayment speeds and credit risk. Prices for securities valued using these inputs are received from independent pricing vendors and brokers and are
based on an evaluation of the inputs described. Level 3 includes securities valued using significant unobservable inputswhen market prices are not readily available or reliable, including the fund’s own assumptions in determining the fair
value of investments. Factors used in determining value may include market or issuer specific events or trends, changes in interest rates and credit quality. The inputs or methodology used for valuing securities are not necessarily an
indication of the risks associated with investing in those securities.Changes in valuation techniques and related inputs may result in transfers into or out of an assigned level within the disclosure hierarchy.
|
|
As of January 31, 2020, all investments are categorized as Level 1 under the hierarchy described above.
|
|
The inputs or methodology used for valuing securities are not necessarily an indication of the risk associated with investing in those securities. The following is
a summary of the inputs used in valuing the Fund's assets:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Assets
|
|
Total
|
|
|
Level 1
|
|
Level 2
|
|
Level 3
|
|
Common Stocks
|
$
|
4,738,196
|
|
|
$
|
4,738,196
|
|
$
|
-
|
|
$
|
-
|
|
Real Estate Investment Trust
|
274,228
|
|
|
274,228
|
|
-
|
|
-
|
|
Total Assets
|
|
$
|
5,012,424
|
|
|
$
|
5,012,424
|
|
$
|
-
|
|
$
|
-
|
ITEM 2. CONTROLS AND PROCEDURES
|
(a)
|
The President and Principal Executive Officer and Treasurer and Principal Financial Officer have concluded that the registrant’s disclosure controls and procedures (as defined in Rule 30a-3(c)) under the Investment Company Act of 1940,
are effective based on their evaluation of these disclosure controls and procedures required by Rule 30a-3(b) under the Investment Company Act of 1940 and Rules 13a-15(b) or 15d-15(b) under the Securities Exchange Act of 1934 as of a date
within 90 days of the filing of this report.
|
|
(b)
|
There were no changes in the registrant's internal control over financial reporting (as defined in Rule 30a-3(d) under the Investment Company Act of 1940) that occurred during the registrant’s last fiscal quarter that have materially
affected, or are reasonably likely to materially affect, the registrant’s internal control over financial reporting.
|
ITEM 3. EXHIBITS
Certifications of the President and Principal Executive Officer and Treasurer and Principal Financial Officer as required pursuant to Rule 30a-2(a) under the Investment Company Act of 1940 are filed with this Form N-Q
as exhibits.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934 and the Investment Company Act of 1940, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly
authorized.
|
|
Amplify ETF Trust
|
|
|
|
|
|
|
|
|
|
|
|
/s/ Christian Magoon
|
|
|
By:
|
Christian Magoon
President and Principal Executive Officer
|
|
|
|
|
|
|
Date:
|
March 10, 2020
|
|
|
|
|
Pursuant to the requirements of the Securities Exchange Act of 1934 and the Investment Company Act of 1940, this report has been signed below by the following persons on behalf of the registrant and in the capacities
and on the dates indicated.
|
|
|
|
|
|
|
/s/ Christian Magoon
|
|
|
By:
|
Christian Magoon
President and Principal Executive Officer
|
|
|
|
|
|
|
Date:
|
March 10, 2020
|
|
|
|
|
|
|
|
|
|
|
|
/s/ Bradley H. Bailey
|
|
|
By:
|
Bradley H. Bailey
Principal Financial Officer
|
|
|
|
|
|
|
Date:
|
March 10, 2020
|